A-PREDICT: A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
Study Details
Study Description
Brief Summary
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy. Axitinib will given twice daily by mouth according to tolerability of treatment, for as long as patients are deriving clinical benefit. Blood and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of treatment response. The primary clinical objective of this study is to define the activity of axitinib given to patients with metastatic renal cell carcinoma unsuitable for nephrectomy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
A-PREDICT is a single arm, single agent, open label, multicentre, phase II study of axitinib in patients with metastatic renal cell carcinoma of predominant clear cell histology and unsuitable for debulking nephrectomy (as judged by the treating clinician). Patients who have provided consent and have satisfied the eligibility criteria will be registered into the trial.
The starting dose of axitinib will be 5 mg twice daily by mouth, escalating to a maximum of 10mg twice daily by mouth according to tolerability of treatment, for as long as patients are deriving clinical benefit. Treatment will be paused for one week prior to percutaneous biopsy of the primary on day 1 week 9. Disease progression will be evaluated according to RECIST v1.1 criteria 8 weeks after commencing treatment, at 8 weekly intervals to 6 months and 3 monthly thereafter. Blood and tumour tissue samples will be taken prior to and during therapy to evaluate biomarkers of treatment response. Nephrectomy will be carried out on any patient who becomes suitable in the opinion of the treating clinician during the course of the trial. Where possible, tissue samples will be taken from resected specimens. Response to axitinib in marker lesions will be correlated with changes in biomarkers.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Axitinib Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg. |
Drug: Axitinib
Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.
Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.
Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.
Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Freedom from progression at 6 months [6 months]
The proportion of study participants alive and progression free at 6 months (day 1 week 25 visit). Progression will be measured from the date of study entry (registration date) until the first date of either death or confirmed progressive disease according to RECIST. Patients alive and free from progression will be censored at the date of last follow-up. The proportion of patients progression free at 6 months will be reported with 95% confidence interval. In addition, progression free survival will be presented using the Kaplan Meier product limit method with median progression free survival reported. A blinded central review of CT scans will be conducted for verification purposes.
Secondary Outcome Measures
- Best overall response [During treatment +30 days]
Best tumour response that is achieved during or within 30 days after termination of axitinib that is confirmed according to RECIST
- Progression free survival [Study duration (assessed week 9, 17, 25, and 4 weekly until progression)]
Progression-free survival (PFS) will be measured from the date of registration until first date of either death or confirmed progressive disease according to RECIST 1.1. Time to last follow-up will be used if patient has not progressed or died and PFS time for the patient will be considered censored. A Kaplan Meier graph and median survival time will be presented.
- Overall survival [Study duration (estimated median overall survival (OS) of 10.9 months)]
Overall survival will be measured from the date of registration until the date of death due to any cause. Time to last follow-up will be used if patient has not died and survival time for the patient will be considered censored.
- Safety and toxicity of axitinib (by NCI CTC grading version 4) [Treatment duration (at least 4 weekly, and again at disease progression - likely to be 6 months)]
- Number of patients who become suitable for nephrectomy as a consequence of therapy with axitinib [Study duration (assessed by clinician over treatment duration which is estimated at 6 months)]
The proportion of patients who undergo nephrectomy following registration as a result of treatment with axitinib will be reported with 95% confidence intervals.
Other Outcome Measures
- EXPLORATORY ENDPOINT: Molecular and pathological changes in biomarkers as a consequence of axitinib therapy [Treatment duration (Baseline, Day 1 week 8, and again at disease progression)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed metastatic renal cell carcinoma of predominant clear cell histology
-
Unsuitable for nephrectomy
-
Unsuitable for 'watch and wait' policy
-
No prior systemic therapy for renal cell carcinoma
-
Measurable metastatic disease using RECIST v1.1
-
Life expectancy 12 weeks or greater
-
ECOG performance status 0 or 1
-
Adequate organ function as defined by serum aspartate transaminase (AST) or serum alanine transaminase (ALT) ≤2.5 x upper limit of normal (ULN), or AST and ALT ≤5 x ULN if liver function abnormalities are due to liver metastases; total serum bilirubin ≤1.5 x ULN
-
Adequate haematological function as defined by absolute neutrophil count (ANC) ≥1500/μL, platelets ≥75,000/μL, haemoglobin ≥9.0 g/dL and prothrombin time (PT) ≤1.5 x ULN
-
Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min;
-
Urinary protein <2+ by urine dipstick.
-
No evidence of pre-existing uncontrolled hypertension
-
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment.
-
Willingness and ability to comply with study procedures, including tumour biopsies.
-
Written informed consent
Exclusion Criteria:
-
The presence of intracranial disease, unless stable >6 months. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. All patients previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days.
-
The presence of active second malignancy.
-
Women who are pregnant or are breastfeeding. Female patients must be surgically sterile, be postmenopausal, or must agree to use effective contraception during the period of therapy.
-
Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy.
-
Current signs or symptoms of severe progressive or uncontrolled hepatic, endocrine, pulmonary disease other than directly related to RCC.
-
Gastrointestinal abnormalities including:
-
inability to take oral medication;
-
requirement for intravenous alimentation;
-
prior surgical procedures affecting absorption including total gastric resection;
-
treatment for active peptic ulcer disease in the past 6 months;
-
active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
-
malabsorption syndromes.
-
Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (see section 8.12, concomitant therapy).
-
Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (see section 8.12, concomitant therapy).
-
Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is allowed.
-
Active seizure disorder, spinal cord compression, or carcinomatous meningitis.
-
Any of the following within 12 months prior to study entry: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack.
-
Deep vein thrombosis or pulmonary embolism within 6 months prior to study entry.
-
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
-
Known galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Royal Marsden Hospital - sutton | London | Sutton | United Kingdom | SM2 5PT |
| 2 | Addenbrooke's Hospital | Cambridge | United Kingdom | CB2 0QQ | |
| 3 | Royal Marsden Hospital | London | United Kingdom | SW3 6JJ | |
| 4 | Christie Hospital | Manchester | United Kingdom | M20 4BX | |
| 5 | Derriford Hospital | Plymouth | United Kingdom | PL6 8DH | |
| 6 | Royal Surrey County Hospital | Surrey | United Kingdom | GU2 7XX |
Sponsors and Collaborators
- Institute of Cancer Research, United Kingdom
- Pfizer
- Royal Marsden NHS Foundation Trust
Investigators
- Principal Investigator: James Larkin, Royal Marsden Hospital London
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ICR-CTSU/2011/10033